Market closedNon-fractional
Evolus/EOLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Evolus
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Ticker
EOLS
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Newport Beach, United States
Employees
279
Website
www.evolus.com
Evolus Metrics
BasicAdvanced
$759M
Market cap
-
P/E ratio
-$1.04
EPS
1.48
Beta
-
Dividend rate
Price and volume
Market cap
$759M
Beta
1.48
Financial strength
Current ratio
3.211
Quick ratio
2.803
Long term debt to equity
680.475
Total debt to equity
686.721
Interest coverage (TTM)
-2.10%
Management effectiveness
Return on assets (TTM)
-10.69%
Return on equity (TTM)
-472.61%
Valuation
Price to revenue (TTM)
3.175
Price to book
40.7
Price to tangible book (TTM)
-15.21
Price to free cash flow (TTM)
-26.878
Growth
Revenue change (TTM)
40.45%
Earnings per share change (TTM)
-18.13%
3-year revenue growth (CAGR)
55.63%
3-year earnings per share growth (CAGR)
-35.88%
What the Analysts think about Evolus
Analyst Ratings
Majority rating from 8 analysts.
Evolus Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$59M
-2.63%
Net income
-$13M
11.02%
Profit margin
-22.09%
14.04%
Evolus Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.19
-$0.16
-$0.12
-$0.09
-
Expected
-$0.19
-$0.17
-$0.07
-$0.11
-$0.03
Surprise
-2.26%
-8.05%
79.10%
-14.29%
-
Evolus News
AllArticlesVideos
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
Business Wire·1 month ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 months ago
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Evolus stock?
Evolus (EOLS) has a market cap of $759M as of July 27, 2024.
What is the P/E ratio for Evolus stock?
The price to earnings (P/E) ratio for Evolus (EOLS) stock is 0 as of July 27, 2024.
Does Evolus stock pay dividends?
No, Evolus (EOLS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Evolus dividend payment date?
Evolus (EOLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Evolus?
Evolus (EOLS) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Evolus stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.